0.6614
Verrica Pharmaceuticals Inc stock is traded at $0.6614, with a volume of 344.96K.
It is up +1.89% in the last 24 hours and up +3.17% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.6491
Open:
$0.67
24h Volume:
344.96K
Relative Volume:
0.71
Market Cap:
$58.25M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-0.4499
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-4.01%
1M Performance:
+3.17%
6M Performance:
-69.66%
1Y Performance:
-88.08%
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VRCA
Verrica Pharmaceuticals Inc
|
0.6614 | 58.25M | 5.12M | -67.00M | -38.94M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.36 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
688.89 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
243.16 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
112.86 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-25-23 | Upgrade | Needham | Hold → Buy |
Mar-22-23 | Initiated | Jefferies | Buy |
Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-14-21 | Initiated | RBC Capital Mkts | Outperform |
Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
Jun-24-20 | Initiated | Northland Capital | Outperform |
Mar-24-20 | Initiated | Needham | Buy |
Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 - The Manila Times
When Will Verrica Pharmaceuticals Release Its 2024 Financial Results? - StockTitan
Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference - MSN
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Verrica Pharmaceuticals stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.61 - Investing.com
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Can Verrica Pharmaceuticals' CEO Presentation Reveal New Growth Strategies at TD Cowen Conference? - StockTitan
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston - The Manila Times
Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals secures covenant waiver By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals secures covenant waiver - Investing.com India
Common Warts Market to Expand Significantly by 2034, States - openPR
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Verrica reports high response rate in skin cancer study - MSN
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Genital Warts Market Size to Reach USD 1,435.0 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Barclays PLC Grows Stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders - Simply Wall St
Verrica Showcases Promising VP-315 Data at Dermatology Conference - MyChesCo
New Data Suggest Potential of VP-315 as Treatment for Basal Cell Carcinoma - MD Magazine
Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire
Verrica reports high response rate in skin cancer study By Investing.com - Investing.com Canada
Verrica's Skin Cancer Drug Shows 97% Response Rate in Phase 2 Trial, Complete Clearance in Half of Tumors - StockTitan
Certain Pre-Funded Warrants of Verrica Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2025. - Marketscreener.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC - Defense World
Barclays PLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Jefferies cuts Verrica stock target to $3, maintains Buy rating - Investing.com
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
State Street Corp Buys 61,041 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
60,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Sanctuary Advisors LLC - Defense World
Needham & Company LLC Reiterates Hold Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MSN
Verrica reports rise in YCANTH applicator units in Q4 By Investing.com - Investing.com South Africa
Verrica reports rise in YCANTH applicator units in Q4 - Investing.com
Verrica Provides Business and Operational Update - GlobeNewswire
Verrica Pharma's YCANTH Sales Surge in Q4; Plans Game-Changing Single Applicator Launch for 2025 - StockTitan
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
Verition Fund Management LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Position Reduced by Fmr LLC - Defense World
Verrica Pharmaceuticals stock hits 52-week low at $0.7 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.7 - Investing.com
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.6% - Defense World
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):